ACADIA Pharmaceuticals Inc (ACAD)vsAlnylam Pharmaceuticals Inc (ALNY)
ACAD
ACADIA Pharmaceuticals Inc
$21.56
-0.74%
HEALTHCARE · Cap: $3.61B
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 291% more annual revenue ($4.29B vs $1.10B). ACAD leads profitability with a 34.3% profit margin vs 12.6%. ALNY appears more attractively valued with a PEG of 0.48. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ACAD
Buy54
out of 100
Grade: C-
ALNY
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACAD.
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 30 in profit
Keeps 34 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Areas to Watch
Expensive relative to growth rate
Earnings declined 81.8%
Operating margin of -1.7%
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACAD
The strongest argument for ACAD centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 34.3% and operating margin at -1.7%.
Bull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bear Case : ACAD
The primary concerns for ACAD are PEG Ratio, EPS Growth, Operating Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Key Dynamics to Monitor
ACAD profiles as a mature stock while ALNY is a growth play — different risk/reward profiles.
ACAD carries more volatility with a beta of 0.83 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 54/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ACADIA Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?